Abstract
Somatostatin (SRIF, somatotropin release inhibiting factor), discovered for its inhibitory action on growth hormone (GH) secretion from pituitary, is an abundant neuropeptide. Two forms, SRIF14 and SRIF28 exist. Recently, a second family of peptides with very similar sequences and features was described; the cortistatins (CST), CST17 and CST29 which are brain selective. The five cloned SRIF receptors (sst1–5) belong to the G-protein coupled/heptathelical receptor family. Structural and operational features distinguish two classes of receptors; SRIF1-sst2/sst3/sst5 (high affinity for octreotide or seglitide) and SRIF2=sst1/sst4 (very low affinity for the aforementioned ligands). The affinity of SRIF receptors for somatostatins and cortistatins is equally high, and it is not clear whether selective receptors do exist for one or the other of the peptides. Several radiologlands label all SRIF receptors, e.g., [125I]LTT-SRIF28, [125I]CGP23996, [125I]Tyr10cortistatin or [125I]Tyr11SRIF14. In contrast, [125I]Tyr3octreotide, [125I]BIM23027, [125I]MK678 or [125I]D-Trp8SRIF14 label predominantly SRIF1 sites, especially sst2 and possibly sst5 receptors. In brain, [125I]Tyr3octreotide binding equates with sst2 receptor mRNA distribution. Native SRIF2 receptors can be labeled with [125I]SRIF14 in the presence of high NaCl in brain (sst1) or lung (sst4) tissue. Short cyclic or linear peptide analogs show selectivity for sst2/sst5 (octreotide, lanreotide, BIM 23027), sst1 (CH-275), sst3 (sst3-ODN-8), or sst5 receptors (BIM 23268); although claims for selectivity have not always been confirmed. Beta peptides with affinity for SRIF receptors are also reported. The general lack of SRIF receptor antagonists is unique for peptide receptors, although CYN 154806 is a selective and potent sst2 antagonist. Nonpeptide ligands are still rare, although a number of molecules have been reported with selectivity and potency for sst1 (L 757,519), sst2 (L 779,976), sst3 (L 796,778), sst4 (NNC 26-9100, L 803,087) or sst1/sst5 receptors (L 817,018). Such molecules are essential to establish the role of SRIF receptors, e.g., sst1 in hypothalamic glutamate currents: sst2 in inhibiting release of GH, glucagon, TSH, gastric acid secretion, pain, seizures and tumor growth, and sst5 in vascular remodeling and inhibition of insulin and GH release.
Similar content being viewed by others
References
Aguila M. C., Dees W. L., Haensly W. E., and McCann S. M. (1991) Evidence that somatostatin is localized and synthesized in lymphoid organs. Proc. Natl. Acad. Sci. USA 88, 11,485–11,489.
Ankersen M., Crider M., Liu S., Ho B., Andersen H. S., and Stidsen C. (1998) Discovery of a Novel Non-Peptide Somatostatin Agonist with SST4 Selectivity. J. Am. Chem. Soc. 120, 1368–1373.
Bass R. T., Buckwalter B. L., Patel B. P., et al. (1996) Identification and characterization of novel somatostatin antagonists. Mol. Pharmacol. 50, 709–715.
Bauer W., Briner U., Doepfner W., et al. (1982) SMS201-995: a very potent and selective octapeptide analog of SRIF with prolonged action. Life Sci. 31, 1133–1140.
Baumbach W. R., Carrick T. A., Pausch M. H., et al. (1998) A linear hexapeptide somatostatin antagonist blocks somatostatin activity in vitro and influences growth hormone release in rats. Mol. Pharmacol. 54, 864–873.
Baumeister H., Kreuzer O. J., Roosterman D., Schafer J., and Meyerhof W. (1998) Cloning, expression, pharmacology and tissue distribution of the mouse SST receptor subtype 5. J. Neuroendocrinol. 10, 283–290.
Brazeau P., Vale W., Burgus R., et al. (1973) Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 179, 77–79.
Bruno J. F., Xu Y., Song J., and Berelowitz M. (1992) Molecular cloning and functional expression of a brain-specific somatostatin receptor. Proc. Natl. Acad. Sci. USA 89, 11,151–11,155.
Bruns C., Raulf F., Hoyer D., Schloos J., Luebbert H., and Weckbecker G. (1996) Binding properties of somatostatin receptor subtypes. Metab. Clin. Exp. 44, 17–20.
Carruthers A. M., Warner A. J., Michel A. D., Feniuk W., and Humphrey P. P. A. (1999) Activation of adenlyate cyclase by human recombinant sst5 receptors expressed in CHO-K1 cells and involvement of G.alpha.s proteins. Br. J. Pharmacol. 126, 1221–1229.
Corness J. D., Demchyshyn L. L., Seeman P., et al. (1993) A human somatostatin receptor (SSTR3), located on chromosome 22, displays preferential affinity for somatostatin-14 like peptides. FEBS Lett. 321, 279–284.
Coy D. H. and Taylor J. E. (1999) Development of somatostatin agonists with high affinity and specificity for the human and rat type 5 receptor subtype. Pept. Proc. Am. Pept. Symp. 15, 559–560.
Dasgupta P., Singh A. T., and Mukherjee R. (2000) Lipophilization of somatostatin analog RC-160 with long chain fatty acid improves its anti-proliferative activity on human oral carcinoma cells. Life Sci. 66, 1557–1570.
De Lecea L., Criado J. R., Prospero-Garcia O., et al. (1996) A cortical neuropeptide with neuronal depressant and sleep-modulating properties. Nature 381, 242–245.
Delesque N., Buscail L., Esteve J. P., et al. (1997) SST2 Somatostatin receptor expression reverses tumorigenicity of human pancreatic cancer cells. Cancer Res. 57, 956–962.
Demchyshyn L. L., Srikant C. B., Sunahara R. K., et al. (1993) Cloning and expression of a human somatostatin-14-selective receptor variant (somatostatin receptor 4) located on chromosome 20. Mol. Pharmacol. 43, 894–901.
Epelbaum J. (1986) Somatostatin in the central nervous system: physiology and pathological modifications. Prog. Neurobiol. (Oxford) 27, 63–100.
Epelbaum J., Dournaud P., Fodor M., and Viollet C. (1994) The neurobiology of somatostatin. Crit. Rev. Neurobiol. 8, 25–44.
Feniuk W., Dimech J., and Humphrey P. P. A. (1993) Characterization of somatostatin receptors in guinea pig isolated ileum, vas deferens and right atrium. Br. J. Pharmacol. 110, 1156–1164.
Feniuk W., Jarvie E., Luo J., and Humphrey P. P. A. (2000) Selective somatostatin sst2 receptor blockade with the novel cyclic octapeptide, CYN-154806. Neuropharmacology 39, 1443–1450.
Fukusumi S., Kitada C., Takekawa S., et al. (1997) Identification and characterization of a novel human cortistatin-like peptide. Biochem. Biophys. Res. Commun. 232, 157–163.
Gademann K., Ernst M., Hoyer D., and Seebach D. (1999) Synthesis and biological evaluation of a cyclo-β-tetrapeptide as a somatostatin analog. Angew. Cehm. (Int. Ed.) 38, 1223–1226.
Gademann K., Ernst M., Seebach D., and Hoyer D. (2000) The cyclo-β-tetrapeptide (β-Hphe-β-HThr-β-HLys-β-HTrp): synthesis, NMR structure in methanol solution, and affinity for human somatostatin receptors. Helv. Chim. Acta. 83, 16–33.
Gademann K., Kimmerlin T., Hoyer D., and Seebach D. (2001) Peptide Folding Induces High and Selective Affinity of a Linear and Small β-Peptide to the Human Somatostatin Receptor 4. J. Med. Chem. 44, 2460–2468.
Gu Z. F., Corleto V. D., Mantey S. A., Coy D. H., Maton P. N., and Jensen R. T. (1995) Somatostatin receptor 3 mediates the inhibitory action of somatostatin on gastric smooth muscle cells. Am. J. Physiol. 268, G739-G748.
Hocart S. J., Jain R., Murphy W. A., Taylor J. E., and Coy D. H. (1999) Highly Potent Cyclic Disulfide Antagonists of Somatostatin. J. Med. Chem. 42, 1863–1871.
Hoyer D., Luebbert H., and Bruns C. (1994) Molecular pharmacology of somatostatin receptors. Naunyn-Schmiedeberg’s Arch. Pharmacol. 350, 441–453.
Kluxen F. W., Bruns C., and Luebbert H. (1992) Expression cloning of a rat brain somatostatin receptor cDNA. Proc. Natl. Acad. Sci. USA 89, 4618–4622.
Koenig J. A., Edwardson J. M., and Humphrey P. P. A. (1997) Somatostatin receptors in Neuro2A neuroblastoma cells: ligand internalization. Br. J. Pharmacol. 120, 52–59.
Krenning E. P., Valkema R., Kooij P. P. M., et al. (2000) The role of radioactive somatostatin and its analogues in the control of tumor growth. Recent Results Cancer Res. 153, 1–13.
Lamberts S. W. J., Krenning E. P., and Reubi J.-C. (1991) The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr. Rev. 12, 450–482.
Lamberts S. W., van der Lely A. J., De Herder W. W., and Hofland L. J. (1996) Octreotide. N. Engl. J. Med. 334, 246–254.
Lanneau C., Bluet-Pajot M. T., Zizzari P., et al. (2000) Involvement of the sst1 somatostatin receptor subtype in the intrahypothalamic neuronal network regulating growth hormone secretion: an in vitro and in vivo antisense study. Endocrinology 141, 967–979.
Liapakis G., Hoeger C., Rivier J., and Reisine T. (1996) Development of a selective agonist at the somatostatin receptor subtype SSTR1. J. Pharmacol. Exp. Ther. 276, 1089–1094.
Liu J., Underwood D. J., Cascieri M. A., et al. (2000) Synthesis of a substance P antagonist with a somatostatin scaffold: factors affecting agonism / antagonism at GPCRs and the role of pseudosymmetry. J. Med. Chem. 43, 3827–3831.
Lloyd K. C. K., Wang J., Aurang K., Gronhed P., Coy D. H., and Walsh J. H. (1995) Activation of somatostatin receptor subtype 2 inhibits acid secretion in rats. Am. J. Physiol. 268, G102-G106.
Mandarino L., Stenner D., Blanchard W., et al. (1981) Selective effects of somatostatin- 14, -25 and -28 on in vitro insulin and glucagon secretion. Nature 291, 76–77.
Martin J. L., Chesselet M. F., Raynor K., Gonzales C., and Reisine T. (1991) Differential distribution of somatostain receptor subtypes in rat brain revealed by newly developed somatostatin analogs. Neuroscience (Oxford) 41, 581–593.
McHenry L., Murthy K. S., Grider J. R., and Makhlouf G. M. (1991) Inhibition of muscle cell relaxation by somatostatin: tissue-specific, cAMP-dependent, pertussis toxin-sensitive. Am. J. Physiol. 261, G45-G49.
McKeen E. S., Feniuk W., Michel A. D., Kidd E. J., and Humphrey P. P. A. (1996) Identification and characterization of heterogeneous somatostatin binding sites in rat distal colonic mucosa. Naunyn-Schmiedeberg’s Arch. Pharmacol. 354, 543–549.
Meyerhof W. (1998) The elucidation of somatostatin receptor functions: a current view. Rev. Physiol. Biochem. Pharmacol. 133, 55–105.
Meyerhof W., Paust H. J., Schonrock C., and Richter D. (1991) Cloning of a cDNA encoding a novel putative G-protein-coupled receptor expressed in specific rat brain regions. DNA Cell Biol. 10, 689–694.
Meyerhof W., Wulfsen I., Schoenrock C., Fehr S., and Richter D. (1992) Molecular cloning of a somatostatin-28 receptor and comparison of its expression in specific rat brain regions. DNA Cell Biol. 10, 689–694.
Meyerhof W., Wulfsen I., Schoenrock C., Fehr S., and Richter D. (1992) Molecular cloning of a somatostatin-28 receptor and comparison of its expression pattern with that of a somatostatin-14 receptor in rat brain. Proc. Natl. Acad. Sci. USA 89, 10,267–10,271.
Moldovan S., DeMayo F., and Brunicardi F. C. (1998) Cloning of the mouse SSTR5 gene. J. Surg. Res. 76, 57–60.
Nehring R. B., Richter D., and Meyerhof W., (2000) Glycosylation affects agonist binding and signal transduction of the rat somatostatin receptor subtype 3. J. Physiol. (Paris) 94, 185–192.
O’Carroll A. M., Lolait S. J., Koenig M., and Mahan L. C. (1992) Molecular cloning and expression of a pituitary somatostatin receptor with preferential affinity for somatostatin-28. Mol. Pharmacol. 42, 939–946.
Panetta R., Greenwood M. T., Warszynska A., et al. (1994) Molecular cloning, functional characterization, and chromosomal localization of a human somatostatin receptor (somatostatin receptor type 5) with preferential affinity for somatostatin-28. Mol. Pharmacol. 45, 417–427.
Patel Y. C. (1997) Molecular pharmacology of somatostatin receptor subtypes. J. Endocrin. Invest. 20, 348–367.
Patel Y. C. (1999) Somatostatin and Its Receptor Family. Front. Neuroendocrinol. 20, 157–198.
Patel Y. C. and Galanopoulou A. (1995) Processing and intracellular targeting of prosomatostatin-derived peptides: the role of mammalian endoproteases. Ciba Found. Symp. 190, 26–50.
Patel Y. C. and O’Neil W. (1988) Peptides derived from cleavage of prosomatostatin at carboxyl- and aminoterminal segments. Characterization of tissue and secreted forms in the rat. J. Biol. Chem. 263, 745–751.
Patel Y. C. and Srikant C. B. (1994) Subtype selectivity of peptide analogs for all five cloned human somatostatin receptors (hsstr 1–5). Endocrinology 135, 2814–2817.
Patel Y. C. and Srikant C. B. (1997) Somatostatin receptors. Trends Endocrinol. Metab. 8, 398–405.
Patel Y. C., Greenwood M., Kent G., Panetta R., and Srikant C. B. (1993) Multiple gene transcripts of the somatostatin receptor SSTR2: Tissue selective distribution and cAMP regulation. Biochem. Biophys. Res. Commun. 192, 288–294.
Pradayrol L., Jornvall H., Mutt V., and Ribet A. (1980) N-terminally extended somatostatin: the primary structure of somatostatin-28. FEBS Lett. 109, 55–58.
Prinz C., Sachs G., Walsh J. H., Coy D. H., and Wu S. V. (1994) The somatostatin receptor subtype on rat enterochromaffinlike cells. Gastroenterology 107, 1067–1074.
Puebla L., Mouchantaf R., Sasi R., et al. (1999) Processing of rat preprocortistatin in mouse AtT-20 cells. J. Neurochem. 73, 1273–1277.
Raynor K. and Reisine T. (1992) Somatostatin receptors. Crit. Rev. Neurobiol. 6, 273–289.
Raynor K., Coy D. C., and Reisine T. (1992) Analogs of somatostatin bind selectively to brain somatostatin receptor subtypes. J. Neurochem. 59, 1241–1250.
Raynor K., Murphy W. A., Coy D. H., et al. (1993a) Cloned somatostatin receptors: Identification of subtype-selective peptides and demonstration of high affinity binding of linear peptides. Mol. Pharmacol. 43, 838–844.
Raynor K., O’Carroll A. M., Kong H., et al. (1993b) Characterization of cloned somatostatin receptors SSTR4 and SSTR5. Mol. Pharmacol. 44, 385–392.
Reichlin S. (1983) Somatostatin. N. Engl. J. Med. 309, 1556–1563.
Reisine T. and Bell G. I. (1995) Molecular biology of somatostatin receptors. Endocr. Rev. 16, 427–442.
Reubi J. C. (1984) Evidence for two SRIF-14 receptor types in rat brain cortex. Neurosci. Lett. 49, 259–263.
Reubi J. C., Schaer J. C., Waser B., Hoeger C., and Rivier J. (1998) A selective analog for the somatostatin sst1-receptor subtype expressed by human tumors. Eur. J. Pharmacol. 345, 103–110.
Reubi J. C., Schaer J. C., Wenger S., et al. (2000) SST3-selective potent peptide somatostatin receptor antagonists. Proc. Natl. Acad. Sci. USA 97, 13,973–13,978.
Rocheville M., Lange D. C., Kumar U., Patel S. C., Patel R. C., and Patel Y. C. (2000a) Receptors for dopamine and somatostatin: Formation of hetero-oligomers with enhanced functional activity. Science 288, 154–157.
Rocheville M., Lange D. C., Kumar U., Sasi R., Patel R. C., and Patel Y. C. (2000b) Subtypes of the somatostatin receptor assemble as functional homo- and heterodimers. J. Biol. Chem. 275, 7862–7869.
Rohrer L., Raulf F., Bruns C., Buettner R., Hofstaedter F., and Schuele R. (1993) Cloning and characterization of a fourth human somatostatin receptor. Proc. Natl. Acad. Sci. USA 90, 4196–4200.
Rohrer S. P. and Berk S. C. (1999) Development of somatostatin receptor subtype selective agonists through combinatorial chemistry. Curr. Opin. Drug Discovery Dev. 2, 293–303.
Rohrer S. P. and Schaeffer J. M. (2000) Identification and characterization of subtype selective somatostatin receptor agonists. J. Physiol. (Paris) 94, 211–215.
Rohrer S. P., Birzin E. T., Mosley R. T., et al. (1998) Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry. Science (Washington, D.C.) 2878, 737–740.
Rossowsi W. J. and Coy D. H. (1994) Specific inhibition of rat pancreatic insulin or glucagon release by receptor-selective somatostatin analogs. Biochem. Biophys. Res. Commun. 205, 341–346.
Rossowski W. J., Gu Z. F., Akarca U. S., Jensen R. T., and Coy D. H. (1994) Characterization of somatostatin receptor subtypes controlling rat gastric acid and pancreatic amylase release. Peptides 15, 1421–1424.
Schwabe W., Brennan M. B., and Hochgeschwender U. (1996) Isolation and characterization of the mouse (Mus musculus) somatostatin receptor type-4-encoding gene (mSSTR4). Gene 168, 233–235.
Sellers L. A., Alderton F., Carruthers A. M., Schindler M., and Humphrey P. P. A. (2000) Receptor isoforms mediate opposing proliferative effects through G.beta.gamma.-activated p38 or Akt pathways. Mol. Cell. Biol. 20, 5974–5985.
Sharma K. and Srikant C. B. (1998) Induction of wild-type p53, Bax, and acidic endonuclease during somatostatin-signaled apoptosis in MCF-7 human breast cancer cells. Int. J. Cancer 76, 259–266.
Shimon I., Taylor J. E., Dong J. Z., et al. (1997) Somatostatin receptor subtype specificity in human fetal pituitary cultures. Differential role of SSTR2 and 5 for growth hormone, thyroid-stimulating hormone, and prolactin regulation. J. Clin. Invest. 99, 789–798.
Siehler S. and Hoyer D. (1999a) Characterization of human recombinant somatostatin receptors. 2. Modulation of GTP.gamma.S binding. Naunyn-Schmiedeberg’s Arch. Pharmacol. 360, 500–509.
Siehler S. and Hoyer D. (1999b) Characterization of human recombinant somatostatin receptors. 3. Modulation of adenylate cyclase activity. Naunyn-Schmiedeberg’s Arch. Pharmacol. 360, 510–521.
Siehler S. and Hoyer D. (1999c) Characterization of human recombinant somatostatin receptors. 4. Modulation of phospholipase C activity. Naunyn-Schmiedeberg’s Arch. Pharmacol. 360, 522–532.
Siehler S, Seuwen K., and Hoyer D. (1998) [125I]Tyr10-cortistatin14 labels all five somatostatin receptors. Naunyn-Schmiedeberg’s Arch. Pharmacol. 357, 483–489.
Siehler S., Seuwen K., and Hoyer D. (1999) Characterization of human recombinant somatostatin receptors. 1. Radioligand binding studies. Naunyn-Schmiedeberg’s Arch. Pharmacol. 360, 488–499.
Souers A. J., Rosenquist A., Jarvie E. M., Ladlow M., Feniuk W., and Ellman J. A. (2000) Optimization of a somatostatin mimetic via constrained amino acid and backbone incorporation. Bioorg. Med. Chem. Lett. 10, 2731–2733.
Stolz B., Weckbecker G., Smith-Jones P.M., Albert R., Raulf F., and Bruns C. (1998) The somatostatin receptor-targeted radiotherapeutic [90Y-DOTA-dPhe1,Tyr3] octreotide (90Y-SMT 487) eradicates experimental rat pancreatic CA 20948 tumors. Eur. J. Nucl. Med. 25, 668–674.
Strowski M. Z., Parmar R. M., Blake A. D., and Schaeffer J. M. (2000) Somatostatin inhibits insulin and glucagon secretion via two receptor subtypes: an in vitro study of pancreatic islets from somatostatin receptor 2 knockout mice. Endocrinology 141, 111–117.
Tran V. T., Beal M. F., and Martin J. B. (1985) Two types of somatostatin receptors differentiated by cyclic somatostatin analogs. Science (Washington, D.C.) 228, 492–495.
Vale W., Rivier C., Brazeau P., and Guillemin R. (1974) Effects of somatostatin on the secretion of thyrotropin and prolactin. Endocrinology 95, 968–977.
Vanetti M., Kouba M., Wang X, Vogt G., and Hoellt V. (1992) Cloning and expression of a novel mouse somatostatin receptor (SSTR2B). FEBS Lett. 311, 290–294.
Warhurst G., Higgs N. B., Fakhoury H., Warhurst A. C., Garde J., and Coy D. H. (1996) Somatostatin receptor subtype 2 mediates somatostatin inhibition of ion secretion in rat distal colon. Gastroenterology 111, 325–3333.
Weckbecker G., Raulf F., Tolcsvai L., and Bruns C. (1996) Potentiation of the antiproliferative effects of anti- cancer drugs by octreotide in vitro and in vivo. Digestion 57, 22–28.
Weckbecker G., Stolz B., Susini C., and Bruns C. (1999) Aniproliferative somatostatin analogues with potential in oncology, in Ocretotide, the Next Decade (St. Lamberts, ed.), pp. 339–352.
Wilkinson G. F., Feniuk W., and Humphrey P. P. A. (1997) Characterization of human recombinant somatostatin sst5 receptors mediating activation of phosphoinositide metabolism. Br. J. Pharmacol. 121, 91–96.
Xu Y., Song J., Bruno J. F., and Berelowitz M. (1993) Molecular cloning and sequencing of a human somatostatin receptor, hSSTR4. Biochem. Biophys. Res. Commun. 193, 648–652.
Yamada Y., Kagimoto S., Kubota A., et al. (1993a) Cloning, functional expression and pharmacological characterization of a fourth (hSSTR4) and a fifth (hSSTR5) human somatostatin receptor subtype. Biochem. Biophys. Res. Commun. 195, 844–852.
Yamada Y., Post S. R., Wang K., Tager H. S., Bell G. I., and Seino S. (1992a) Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract, and kidney. Proc. Natl. Acad. Sci. USA 89, 251–255.
Yamada Y., Reisine T., Law S. F., et al. (1992b) Somatostatin receptors, an expanding gene family: Cloning and functional characterization of human SSTR3, a protein coupled to adenylyl cyclase. Mol. Endocrinol. 6, 2136–2142.
Yamada Y., Stoffel M., Espinosa R. E. (III), et al. (1993b) Human somatostatin receptor genes: Localization to human chromosomes 14, 17, and 22 and identification of simple tandem repeat polymorphisms. Genomics 15, 449–452.
Yang L., Berk S. C., Rohrer S. P., et al. (1998) Synthesis and biological activities of potent peptidomimetics selective for somatostatin receptor subtype 2. Proc. Natl. Acad. Sci. USA 95, 10,836–10,841.
Yasuda K., Rens-Domiano S., Breder C. D., et al. (1992) Cloning of a novel somatostatin receptor, SSTR3, coupled to adenylyl cyclase. J. Biol. Chem. 367, 20422–20428.
Zaki M., Harrington L., McCuen R., Coy D. H., Arimura A., and Schubert M. L. (1996) Somatostatin receptor subtype 2 mediates inhibition of gastrin and histamine secretion from human, dog, and rat antrum. Gastroenterology 111, 919–924.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hannon, J.P., Nunn, C., Stolz, B. et al. Drug design at peptide receptors. J Mol Neurosci 18, 15–27 (2002). https://doi.org/10.1385/JMN:18:1-2:15
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1385/JMN:18:1-2:15